Advertisement

Topics

ESMO 2017: Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer

22:05 EDT 7 Sep 2017 | ecancermedicalscience

Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid. Most ovarian cancer presents as...

Original Article: ESMO 2017: Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...